DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Cyclophosphamide
Drug: Methotrexate

First Posted Date: 2009-06-22

Last Posted Date: 2022-01-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT00925652

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 6 locations

Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer
Gastric Cancer

Interventions: Drug: Bevacizumab
Drug: Cisplatin
Device: Docetaxel
Drug: Irinotecan

First Posted Date: 2009-06-02

Last Posted Date: 2022-11-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 88

Registration Number: NCT00911820

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 1 locations

Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Vorinostat
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2009-05-29

Last Posted Date: 2018-09-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00910000

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Plerixafor
Drug: bortezomib
Drug: Dexamethasone

First Posted Date: 2009-05-19

Last Posted Date: 2020-06-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00903968

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cape Cod Hospital, Hyannis, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 2 locations

Extended Endocrine Therapy for Premenopausal Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: leuprolide
Drug: letrozole
Drug: zoledronic acid

First Posted Date: 2009-05-18

Last Posted Date: 2016-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT00903162

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Newton Wellesley Hospital, Newton, Massachusetts, United States

and more 1 locations

Skin Cancer Screening and Education at Beaches

Not Applicable

Completed

Conditions: Skin Cancer

Interventions: Behavioral: education about sun protection
Behavioral: biometric feedback
Other: dermatologist skin exam

First Posted Date: 2009-05-07

Last Posted Date: 2014-12-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 634

Registration Number: NCT00894855

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Radiation: Neoadjuvant Short-Course Photon Radiation
Drug: Capecitabine

First Posted Date: 2009-04-28

Last Posted Date: 2018-05-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00889187

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Autologous, Lethally Irradiated Breast Cancer Cells

First Posted Date: 2009-04-13

Last Posted Date: 2022-04-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT00880464

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Carcinoma

Interventions: Drug: Docetaxel
Drug: Placebo
Drug: vandetanib

First Posted Date: 2009-04-13

Last Posted Date: 2018-09-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 149

Registration Number: NCT00880334

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Rapamycin in Relapsed Acute Lymphoblastic Leukemia

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Corticosteroid
Drug: Rapamycin

First Posted Date: 2009-04-02

Last Posted Date: 2016-11-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT00874562

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy